A later study demonstrated that the CX-5461/CX-6258 combination therapy effectively inhibited growth, increased DNA damage responses and suppressed mTOR signalling in four distinct PC PDX models obtained from CRPC patients resistant to second-generation ADT agents, including abiraterone and/or enzalutamide [170]. The gene discussed is MTOR; the disease is pachyonychia congenita.